Status: Recruiting
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. The safety, tolerance, and preliminary clinical efficacy of the TILs will be evaluated.
Participants needed: 40
Trial details
Phase: Phase 1Age: 18-85Biological sex: AllType: InterventionalSponsor: Second Affiliated Hospital of Guangzhou Medical UniversityUpdated: Jun 25, 2024Locations: 1
Eligibility criteria
Patients with advanced cancers that failed to current available therapies; [+4]
Had accepted gene therapy before; [+6]